Gilead Sciences: stocks, financial statements

Dividends News
Favorites

It develops and implements innovative methods of treatment and prevention of severe diseases. The main research focuses on the fight against HIV and AIDS, cancer, hepatitis B and C, that is, specializes mainly in antiviral drugs. New types of treatments for Hematology, liver diseases, inflammatory and infectious diseases are also being produced, including various types of flu virus, including Harvoni and Sovaldi. In addition to the therapeutic direction, systems of specific care for patients with a severe form of the disease are being developed. Serial production of new drugs is concentrated in the regions where the problem of the spread of deadly diseases is most urgent - North and South Africa, Europe, and Asia.

The founder of the company, tried to «recruit» Warren Buffett as an investor and a member of the Board of Directors, but was unsuccessful. A year ago, The Times reported that this «American pharmaceutical firm used a controversial tax loophole to shift almost 20 billion euros of profits through an Irish legal entity in just two years.»

  • GILD Ticker
  • NASDAQ Exchange
  • 11,000 Employees
19 rated
  • $68.77, $-0.52 (-0.75%) Previous Close
  • 6,928,016 Previous Volume
  • $55.19 / $75.59 52 week low / high
  • -9.02% Percent off 52 week high
  • 2021-06-11 Updated
  • 4.00% Dividend Yield (trailing)
  • 4.13% Dividend Yield (forward)
  • 0 Public float
  • 1,254,178,166 Outstanding shares
  • 280.09 P/E
  • 84.31 B Market Cap
Disable ads for free

Financial statements — Gilead Sciences

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
25B 22B 22B 26B 30B
Cost Of Revenue
4.6B 4.7B 4.9B 4.4B 4.3B
Gross Profit
20B 18B 17B 22B 26B
Research and Development
5B 9.1B 5B 3.7B 5.1B
Selling General and Admin
5.2B 4.4B 4.1B 3.9B 3.4B
Operating Expense
21B 18B 14B 12B 13B
Operating Income
4.1B 4.3B 8.2B 14B 18B
Other Income Expense Net
0 0 0 0 0
EBIT
4.1B 4.3B 8.2B 14B 18B
Interest Income
980M 1M 1.1B 1.1B 960M
Pretax Income
1.7B 5.2B 7.8B 14B 17B
Income Tax
1.6B -200M 2.3B 8.9B 3.6B
Minority Interest
-34M -22M 5M 16M -13M
Net Income
120M 5.4B 5.5B 4.6B 14B
Net Income Basic
120M 5.4B 5.5B 4.6B 14B
20 ← 16 2020 2019 2018 2017 2016
Current cash
7.4B 24B 31B 26B 12B
Short term investments
2B 1.4B 740M 1B 1.6B
Receivables
4.9B 3.6B 3.3B 3.9B 4.5B
Inventory
1.7B 920M 810M 800M 1.6B
Other current assets
2B 1.4B 740M 1B 1.6B
Current assets
16B 30B 36B 32B 20B
Long term investments
52B 31B 28B 38B 37B
Property plant equipment
5B 4.5B 4B 3.3B 2.9B
Goodwill
8.1B 4.1B 4.1B 4.2B 1.2B
Intangible assets
33B 14B 16B 17B 9B
Other assets
5.5B 7.4B 2.6B 2.7B 2.6B
Total assets
68B 62B 64B 70B 57B
Accounts payable
840M 710M 790M 810M 1.2B
Current long term debt
2.8B 2.5B 2.7B 0 0
Other current liabilities
7.8B 6.5B 7.1B 11B 8B
Total current liabilities
11B 9.8B 11B 12B 9.2B
Long term debt
29B 22B 25B 31B 26B
Other liabilities
10B 7.1B 7B 7.4B 2B
Minority Interest
19M 130M 150M 59M 480M
Total Liabilities
50B 39B 42B 50B 38B
Common stock
1.3B 1.3B 1.3B 1.3B 1.3B
Retained earning
14B 19B 19B 19B 18B
Treasury stock
0 0 0 0 0
Capital surplus
Shareholder equity
18B 23B 21B 20B 19B
Net tangible assets
-23B 4.6B 1.5B -820M 8.7B
20 ← 16 2020 2019 2018 2017 2016
Net Income
120M 5.4B 5.5B 4.6B 14B
Depreciation
1.5B 1.4B 1.4B 1.3B 1.2B
Changes in receivables
1.3B 260M -520M -660M -1.3B
Changes in inventories
760M 110M 13M -790M -370M
Cash change
-17B -6.6B 4.8B 14B -2.7B
Cash flow
8.2B 9.1B 8.4B 12B 17B
Capital expenditures
-650M -830M -920M -590M -750M
Investments
Investing activity other
Total investing cash flows
-15B -7.8B 14B -16B -12B
Dividends paid
Net borrowings
22B -1.2B -4.4B 3.6B 13B
Other financing cash flows
Cash flow financing
770M -7.6B -12B 3.4B -9.3B
Exchange rate effect